Somatostatin acts by inhibiting the cyclic 3',5'-adenosine monophosphate (cAMP)/protein kinase A pathway, cAMP response element-binding protein (CREB) phosphorylation, and CREB transcription potency

Molecular Endocrinology

Volumn 11, Issue 7, 1997, Pages 859-866

  Tentler, John J ^a   Hadcock, John R ^b   Gutierrez Hartmann, Arthur ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; BINDING PROTEIN; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; PERTUSSIS TOXIN; PHOSPHATASE; SOMATOSTATIN;

ARTICLE; GROWTH HORMONE RELEASE; HORMONAL REGULATION; HORMONE ACTION; HORMONE RESPONSIVE ELEMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CYCLIC AMP RESPONSE ELEMENT-BINDING PROTEIN; CYCLIC AMP-DEPENDENT PROTEIN KINASES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FORSKOLIN; OKADAIC ACID; PEPTIDES, CYCLIC; PHOSPHORYLATION; PROMOTER REGIONS (GENETICS); RATS; RNA, MESSENGER; SIGNAL TRANSDUCTION; SOMATOSTATIN; TRANSCRIPTION, GENETIC;

EID: 0031005019     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.11.7.859     Document Type: Article

References (50)

1. Lamberts SWJ, Krenning EP, Reubi J-C 1991 The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev 12:450-482
2. Lamberts SW, Uitterlinden P, Schuijff PC, Klijn JG 1988 Therapy of acromegaly with sandostatin: the predictive value of an acute test, the value of serum somatomedin-C measurements in dose adjustment and the definition of a biochemical "cure." Clin Endocrinol (Oxf) 29:411-420
3. Barakat S, Melmed S 1989 Reversible shrinkage of a growth hormone-secreting tumor by a long-acting somatostatin analogue, octreotide. Arch Intern Med 149:1443-1445
4. Reubi JC, Laissue JA 1995 Multiple actions in neoplastic disease. Trends Pharmacol Sci 16:110-115
5. Lamberts SWJ, van der Lely A-J, de Herder WW, Hofland LJ 1996 Octreotide. N Engl J Med 334:246-254
6. Bell GI, Reisine T 1993 Molecular biology of somatostatin receptors. Trends Neurosci 16:34-38
7. Bruns C, Weckbecker G, Raulf F, Kaupmann K, Schoeffter P, Hoyer D, Lubbert H 1994 Molecular pharmacology of somatostatin receptor subtypes. Ann NY Acad Sci 733:138-146
8. Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB 1995 The somatostatin receptor family. Life Sci 57:1249-1265
9. Panetta R, Patel YC 1995 Expression of mRNA for all five human somatostatin receptors (hSSTR1-5) in pituitary tumors. Life Sci 56:333-342
10. Law SF, Woulfe D, Reisine T 1995 Somatostatin receptor activation of cellular effector systems. Cell Signal 7:1-8
11. Vanetti M, Kouba M, Wang X, Vogt G, Hollt V 1992 Cloning and expression of a novel mouse somatostatin receptor (SSTR2B). FEBS Lett 311:290-294
12. McCormick A, Brady H, Theill LE, Karin M 1990 Regulation of the pituitary-specific homeobox gene, GHF-1 by cell-autonomous and environmental clues. Nature 345:829-832
13. Burton FH, Hasel KW, Bloom FE, Sutcliffe JG 1991 Pituitary hyperplasia and gigantism in mice caused by a cholera toxin transgene. Nature 350:74-77
14. Struthers RS, Vale WW, Arias C, Sawchenko PE, Montminy MR 1991 Somatotroph hypoplasia and dwarfism in transgenic mice expressing a non-phosphorylatable CREB mutant. Nature 350:622-624
15. Vallar L, Spada A, Giannattasio G 1987 Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566-568
16. Lyons J, Landis CA, Harsh G, Vallar L, Grunewald K, Feichtinger H, Suh Q-Y, Clark OH, Kawasaki E, Bourne HR, McCormick F 1990 Two G protein oncogenes in human endocrine tumors. Science 249:655-659
17. Bertherat J, Chanson P, Montminy M 1995 The cyclic adenosine 3′,5′-monophosphate-responsive factor CREB is constitutively activated in human somatotroph adenomas. Mol Endocrinol 9:777-783
18. Castrillo JL, Theill LE, Karin M 1991 Function of the homeodomain protein GHF1 in pituitary cell proliferation. Science 253:197-199
19. Deutsch PJ, Jameson JL, Habener JF 1987 Cyclic AMP responsiveness of human gondotropin-alpha gene transcription is directed by a repeated 18-base pair enhancer. Alpha-promoter receptivity to the enhancer confers cell-preferential expression. J Biol Chem 262:12169-12174
20. + channels through protein dephosphorylation. Nature 351:570-573
21. Hagiwara M, A Lberts A, Brindle P, Meinkoth J, Feramisco J, Deng T, Karin M, Shenolikar S, Montminy M 1992 Transcription attentuation following cAMP induction requires PP-1-mediated dephosphorylation of CREB. Cell 70:105-113
22. Wadzinski BE, Wheat WH, Jaspers S, Peruski J, LF, Lickteig RL, Johnson GL, Klemm DJ 1993 Nuclear protein phosphatase 2A dephosphorylates protein kinase A-phosphorylated CREB and regulates CREB transcriptional stimulation. Mol Cell Biol 13:2822-2834
23. Wera S, Belayew A, Martial JA 1993 Okadaic acid, a protein phosphatase inhibitor, enhances transcription of a reporter gene containing sequence A of the human prolactin promoter. Mol Endocrinol 7:965-971
24. Gupta SK, Gallego C, Johnson GL 1992 Mitogenic pathways regulated by G protein oncogenes. Mol Biol Cell 3:123-128
25. Dumont JE, Jauniaux JC, Roger PP 1989 The cyclic AMP-mediated stimulation of cell proliferation. Trends Biochem Sci 14:67-71
26. Parma J, Duprez L, Van Sande J, Cochaux P, Gervy C, Mockel J, Dumont J, Vassart G 1993 Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature 365:649-651
27. Juppner H 1995 Functional properties of the PTH/PTHrP receptor. Bone [Suppl] 17:39s-42s
28. Schipani E, Kruse K, Juppner H 1995 A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
29. Laue L, Chan WY, Hsueh AJ, Kudo M, Hsu SY, Wu SM, Blomberg L, Cutler GBJ 1995 Genetic heterogeneity of constitutively activating mutations of the human leutinizing hormone receptor in familial male-limited precocious puberty. Proc Natl Acad Sci USA 92:1906-1910
30. Spiegel AM 1996 Mutations in G proteins and G protein-coupled receptors in endocrine disease. J Clin Endocrinol Metab 81:2434-2342
31. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695
32. Andersen B, Rosenfeld MG 1994 Pit-1 determines cell types during development of the anterior pituitary gland. J Biol Chem 269:29335-29338
33. Godfrey P, Rahal JO, Beamer WG, Copeland NG, Jenkins NA, Mayo KE 1993 GHRH receptor of little mice contains a missense mutation in the extracellular domain that disrupts receptor function. Nat Gen 4:227-232
34. Gaiddon C, Tian J, Loeffler JP, Bancroft C 1996 Constitutively active G(s) alpha-subunits stimulate Pit-1 promoter activity via a protein kinase A-mediated pathway acting through deoxyribonucleic acid binding sites for both Pit-1 and for adenosine 3′,5′-monophosphate response element-binding protein. Endocrinology 137:1286-1291
35. Yang IM, Woo JT, Kim SW, Kim JW, YSK, Choi YK 1995 Characteristics of acromegalic patients with a good response to octreotide, a somatostatin analogue. Clin Endocrinol (Oxf) 42:295-301
36. Elsholtz HP, Lew AM, Albert PR, Sundmark VC 1991 Inhibitory control of prolactin and Pit-1 gene promoters by dopamine. J Biol Chem 266:22919-22925
37. Lew AM, Yao H, Elscholtz HP 1994 G(i) alpha 2- and G(o) alpha-mediated signaling in the Pit-1-dependent inhibition of the prolactin gene promoter. Control of transcription by dopamine D2 receptors. J Biol Chem 269:12007-12013
38. Wood DF, Johnston JM, Johnston DG 1991 Dopamine plays an important role in the hypothalamic-pituitary axis where its major effects are to inhibit pituitary hormone secretion and cell division. Clin Endocrinol (Oxf) 35:455-466
39. Colas B, Cambillau C, Buscail L, Zeggari M, Esteve J-P, Lautre V, Thomas F, Vaysse N, Susini C 1992 Stimulation of a membrane tyrosine phosphatase activity by somatostatin analogues in rat pancreatic acinar cells. Eur J Biochem 207:1017-1024
40. Bradford AP, Conrad KE, Wasylyk C, Wasylyk B, Gutierrez-Hartmann A 1995 Functional interaction of c-Ets-1 and GHF-1/Pit-1 mediates Ras activation of pituitary-specific gene expression: mapping of the essential c-Ets-1 domain. Mol Cell Biol 15:2849-2857
41. 2+. Endocrinology 116:591-596
42. 3 cells. J Biol Chem 266:1484-1490
43. 4 pituitary cells by separate, antagonistic signal transduction pathways. Mol Cell Biol 15:6777-6784
44. Linard C, Reyl-Desmars F, Lewin MJ 1992 Somatostatin inhibition of phosphoinositides turnover in isolated rat acinar pancreatic cells: interaction with bombesin. Regul Pept 41:219-226
45. Richardson SB, Laya T, Gibson M, Eyler N, Van Ooy M 1992 Somatostatin inhibits vasopressin-stimulated phosphoinositide hydrolysis and influx of extracellular calcium in clonal hamster beta (HIT) cells. Biochem J 288:847-851
46. Srikant C, Shen S-H 1996 Octapeptide somatostatin analog SMS 201-995 induces translocation of intracellular PTP1C to membranes in MCF-7 human breast adenocarcinoma cells. Endocrinology 137:3461-3468
47. Buscail L, Delesque N, Esteve J-P, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV, Vaysse N, Susini C 1994 Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 91:2315-2319
48. Buscail L, Esteve J-P, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A-M, Bell GI, Schally AV, Vaysse N, Susini C 1995 Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 92:1580-1584
49. Liebow C, Reilly C, Serrano M, Schally AV 1989 Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc Natl Acad Sci USA 86:2003-2007
50. Conrad KE, Gutierrez-Hartmann A 1992 The ras and protein kinase A pathways are mutually antagonistic in regulating rat prolactin promoter activity. Oncogene 7:1279-1286